• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

non-alcoholic fatty liver disease (NAFLD)

Ozempic (semaglutide).
Posted inMetabolism, Research

Ozempic: Before and After. Dozens of Inspiring Weight Loss Success Stories

by Julia Mardi and Tanya von Reuss May 3, 2024May 3, 2024

What can you expect from Ozempic, a miracle drug for weight loss and more? Will your physical appearance change a lot? Will you feel more confident?

weight-loss-pills
Posted inClinical Trials, In the Pipeline, Metabolism

Most Effective Weight Loss Drugs: Present and Future

by Julia Mardi and Timur Burkhanayev July 3, 2022September 20, 2022

Modern pharmacological ways to combat obesity.

Posted inMetabolism, New Drugs, Regulatory

Mounjaro: New Dual-Action Drug for Type 2 Diabetes Mellitus

by Mark Gubar, Tanya von Reuss and Timur Burkhanayev May 17, 2022September 8, 2022

Tirzepatide by Eli Lilly is a powerful new antidiabetic drug.

Liver.
Posted inMetabolism, New Drugs, Regulatory

Lipaglyn: World’s First Drug to Treat Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease

by Tanya von Reuss and Timur Burkhanayev April 6, 2021September 8, 2022

Saroglitazar by Zydus Cadila has opened the doors to a new multi-billion dollar sector of NASH and NAFLD pharmacological treatments.

BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×